Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News| Pulmonary Cell News 8.02 January 24, 2019 | |
 | |
| |
TOP STORYGeneration of Lung Organoids from Human Pluripotent Stem Cells In Vitro Investigators describe a protocol that recapitulates milestones in order to differentiate human pluripotent stem cells into ventral-anterior foregut spheroids and further into two distinct types of organoids: human lung organoids and bud tip progenitor organoids. [Nat Protoc] Abstract | |
| |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors provide evidence that Fc gamma receptor III (FcγRIII) stimulation breaks immune tolerance to bacteria in the human nasal cavity through activation of nasal epithelial cells, which are the first line of defense against invading microbes. [Mucosal Immunol] Full Article The effect of hypercapnia (HC) on Aaenylate cyclase (AC) activity and plasma membrane wound repair was measured in alveolar epithelial cell (AEC) type 1 exposed to normocapnia or HC, ± tromethamine or sodium bicarbonate ± AC probes in a micropuncture model of AEC injury relevant to acute respiratory distress syndrome. [Sci Rep] Full Article Scientists demonstrated that TNF-α could induce necroptosis of human bronchial epithelial (16HBE) cells, and MUC1 expression was increased upon treatment with TNF-α. The coimmunoprecipitation outcomes showed that mucin 1 (MUC1) interacted with receptor-interacting protein kinase-1 but not with RIPK3 in 16HBE cells, and the interaction was augmented by TNF-α. [J Cell Physiol] Full Article To explore the general influence of FH knockout, investigators isolated FH+/- rat and normal rat lung fibroblasts and cultured these cells in vitro. The isolated fibroblasts with the current method were rather homogeneous and were confirmed spindle in morphology, positive for vimentin and negative for α-smooth muscle actin. [Aging (Albany NY)] Full Article LUNG CANCERScientists showed that circRNA 100146 was highly expressed in non-small cell lung cancer (NSCLC) cell lines and the chemically induced malignant transformed bronchial cell line, 16HBE-T, as well as 40 paired tissue samples of NSCLC. Suppression of circRNA 100146 inhibited the proliferation and invasion of cells and promoted apoptosis. [Mol Cancer] Full Article Functional assays were conducted to determine the role of metastasis associated lung adenocarcinoma transcript 1 (MALAT1) in regulating the growth and metastasis of parental and DTX-resistant lung adenocarcinoma cells. Mechanism investigation revealed the mechanism of competing endogenous RNA (ceRNA) pathway. [Mol Ther Nucleic Acids] Abstract A VEGF-A/SOX2/SRSF2 Network Controls VEGFR1 Pre-mRNA Alternative Splicing in Lung Carcinoma Cells In this study, researchers identified VEGF165, a splice variant of VEGF-A, as a regulator of sVEGFR1-i13 expression in these tumors, and further showed that VEGF165 cooperates with the transcription factor SOX2 and the splicing factor SRSF2 to control sVEGFR1-i13 expression. [Sci Rep] Full Article Investigators found that tetracenomycin X showed antitumor activity in vivo and selectively inhibited the proliferation of lung cancer cells without influencing lung fibroblasts. In addition, apoptosis and autophagy did not contribute to the antitumor activity. [Mar Drugs] Full Article Subscribe to one of our other 19 science newsletters such as Cancer Stem Cell News & Human Immunology News. | |
| |
| |
REVIEWSPulmonary Group Two Innate Lymphoid Cells: Surprises and Challenges The authors review the emerging roles of group 2 innate lymphoid cells (ILC2s) in pulmonary homeostasis and discuss recent and surprising advances in our understanding of how hormones, age, neurotransmitters, environmental challenges, and infection influence ILC2s. [Mucosal Immunol] Full Article Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
INDUSTRY NEWSSTEMCELL Technologies has released mTeSR™ Plus, an enhanced version of mTeSR™1, the most widely published feeder- free human pluripotent stem cell maintenance medium. The new medium has undergone successful beta testing with several members of the Stem Cell COREdinates group and has completed rigorous in-house validation testing. [STEMCELL Technologies Inc] Press Release Athersys, Inc. announced summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who are suffering from acute respiratory distress syndrome. The study results provide further confirmation of tolerability and a favorable safety profile associated with MultiStem treatment. [Athersys, Inc.] Press Release Achilles Therapeutics Receives CTA Approval for Phase I/II Study in Non-Small Cell Lung Cancer Achilles Therapeutics announces that its Clinical Trial Application (CTA to conduct a Phase I/II study with its lead product, a tumor-derived T cell therapy targeting clonal neoantigens, in development for the treatment of advanced Non-Small Cell Lung Cancer, has been approved by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency. [Achilles Therapeutics Limited] Press Release X-Rx Announces FDA Acceptance of IND Application for X-165 X-Rx, Inc. announced the US FDA has accepted the company’s Investigational New Drug Application for X-165 being developed for the treatment of Idiopathic Pulmonary Fibrosis. [X-Rx, Inc] Press Release Gala Therapeutics announced that the first patient at Temple Lung Center in Philadelphia, Pennsylvania was treated on January 15th, 2019 as part of the Early Feasibility Study of RheOx™ for chronic bronchitis. Dr. Victor Kim, a leading expert in chronic bronchitis, performed the procedure. [Gala Therapeutics Inc] Press Release Vertex Pharmaceuticals Limited announced that the European Commission has granted approval of the label extension for ORKAMBI® for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. [Vertex Pharmaceuticals Incorporated] Press Release | |
| |
EVENTSNEW Cell Symposia: Hallmarks of Cancer Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Respiratory Research (Monell Chemical Senses Center) Postdoctoral Scholar – Lung Repair & Regeneration (University of California San Francisco) Postdoctoral Position – Lung Cancer (Albert Einstein College of Medicine of Yeshiva University) Postdoctoral Fellow – Respiratory Research (Royal College of Surgeons Ireland) Tenure Track Group Leader – Lung Epidemiology (Helmholtz-Center Munchen) Tenure Track Investigator – Lung Cancer (Northwestern University) Associate/Full Professor – Lung Biology & Medicine (University of California, Davis) Associate Professor – Oncology (University of California, Davis) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
